Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free
Close

Aptose Biosciences Inc (APS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.85 0.00    0.00%
09:30:00 - Real-time Data. Currency in CAD ( Disclaimer )
Type:  Equity
Market:  Canada
  • Volume: 0
  • Bid/Ask: 0.82 / 0.85
  • Day's Range: 0.85 - 0.85
Aptose Biosciences 0.85 0.00 0.00%

Aptose Biosciences Inc Company Profile

 
Get an in-depth profile of Aptose Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

-

Equity Type

ORD

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Contact Information

Top Executives

Name Age Since Title
Brian J. Druker 66 2013 Chairman of Scientific Advisory Board
Stephen B. Howell 77 - Member of Scientific Advisory Board
Michael Andreeff - 2015 Member of Scientific Advisory Board
Erich M. Platzer 72 2014 Independent Director
Mark D. Vincent 69 2007 Independent Director
Denis R. Burger 78 2007 Lead Independent Director
Warren Whitehead 70 2011 Independent Director
Daniel Douglas Von Hoff 74 2013 Member of Scientific Advisory Board
William G. Rice 63 2013 Chairman, President, CEO & Chief Accounting Officer
Carol Gail Ashe 64 2018 Independent Director
Bernd Robert Seizinger 66 2022 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

APS Comments

Write your thoughts about Aptose Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Thao Bui
Thao Bui Jan 25, 2022 6:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
any new ?
Shahan Khan
Shahan Khan Oct 27, 2021 2:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is it time to buy this Stock.....?
Ma Ah
Ma Ah Jul 22, 2021 10:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any thoughts on this?
Liew ST
Liew ST Jun 15, 2021 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2021.06.14. Bought again @ 3.81 after the dive.
Liew ST
Liew ST Jun 08, 2021 10:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2021.06.08. Bought 3.80 and sold 6.80 in March 2021
la la
la la Mar 31, 2021 5:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
target at about 11.40$
Mke Gee
Mke Gee Mar 29, 2021 9:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
100% BUY! Check it out!
Mke Gee
Mke Gee Mar 29, 2021 9:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
U wouldve made 5.78% on your money!
Anthony Gautier
Anthony Gautier Dec 18, 2020 2:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Encouraging newsChairman, President and Chief Executive Officer. “We are encouraged by the continued increase in plasma exposure, and we hope the current and future dose levels will deliver formal responses to these deeply relapsed or refractory CLL patients. In AML, we are pleased by the observation of an anti-leukemic blast reduction from 93% to 10% in one of our first patients who was heavily pretreated with several consecutive FLT3 inhibitors. For APTO-253, we continue to escalate the dose and observe MYC repression, suggesting future potential for broad anti-cancer activity. We are pleased by such indicators of activity from both CG-806 and APTO-253, and we look forward to providing further updates in the first half of 2021 and at the Annual EHA Meeting 2021.”
Anthony Gautier
Anthony Gautier Dec 16, 2020 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
APTO is a LT Stock, I see good things ahead as they get positive results from their studies..I have a good feeling about it, loaded up for LT at this price range
Sky Emperor
SkyEmperor Dec 15, 2020 9:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I got in at 3.98, lets see how will it go
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email